Why It Matters

Invivyd Inc., a small-cap biopharmaceutical company focused on monoclonal antibody therapies for COVID-19, filed an LDA termination lobbying disclosure on April 28, 2026, ending its relationship with King & Spalding LLP just three weeks after the engagement began.

The Invivyd lobbying disclosure records show the registration was filed on April 5, 2026, with King & Spalding LLP lobbying on health issues and manufacturing policy on the company's behalf. The termination came before any compensation was reported, with all three filings in the engagement, including the new client registration, a first quarter 2026 report, and the termination notice, showing a filing amount of zero dollars.

A Minor Loss for King & Spalding

The federal lobbying termination carries little financial weight for King & Spalding. The firm reported approximately $2,057,000 in total lobbying revenue during the first quarter of 2026 across a client base of roughly 25 active clients. Its largest client, Quantum Earth, alone reported $250,000 in fees. W&W Energy LLC and Senior Care Pharmacy Coalition each reported $90,000. Invivyd, by contrast, generated nothing.

Invivyd's Lobbying Footprint

Invivyd Inc. lobbying activities have not been limited to King & Spalding. According to lobbying disclosure records, the company has been running a parallel, multi-track government affairs operation:

  • Forbes Tate Partners LLC was registered to lobby for Invivyd beginning in August 2025, focusing on infectious disease and health issues. The firm reported $60,000 in First Quarter 2026 fees and remains active.
  • In-house lobbying through a registered lobbyist, Ben Kenney, generated $20,000 in reported First Quarter 2026 activity, focused on domestic manufacturing and monoclonal antibody policy.

King & Spalding was the third firm in the mix, and the only one that didn't last.

Broader Context

The Lobbying Invivyd Needed

Invivyd is a company navigating a difficult regulatory and commercial environment. Its lead product, PEMGARDA (pemivibart), received Emergency Use Authorization from the FDA in March 2024 for COVID-19 pre-exposure prophylaxis in immunocompromised patients. But the FDA declined in February 2025 to expand that authorization to cover treatment of mild-to-moderate COVID-19, a setback the company had been pushing for.

PEMGARDA's authorization is also conditioned on variant susceptibility, meaning it is only authorized when variants with substantially reduced susceptibility make up 90 percent or less of circulating strains. That creates persistent commercial uncertainty. The company reported $25.4 million in full-year 2024 net product revenue and flagged a going-concern in its annual filings, reflecting its dependence on a single EUA product and evolving federal COVID policy.

The King & Spalding LLP lobbying registration listed two issue areas, health and manufacturing. Based on Invivyd's business situation, those broad categories almost certainly map to reimbursement and coverage policy for PEMGARDA on the health side, and domestic biologics manufacturing and supply chain concerns on the manufacturing side, both of which require ongoing engagement with Congress and federal agencies.

A Critical Moment for Its Pipeline

The termination comes as Invivyd's pipeline is at an inflection point. The company's next-generation antibody candidate, VYD2311, received FDA Fast Track designation in December 2025, and top-line Phase 3 data was anticipated for mid-2026. Invivyd has also announced advancement of a measles monoclonal antibody candidate, citing the current U.S. measles outbreak as a driver.

Neither development makes the need for government affairs work go away. If anything, it intensifies it. No legislation specifically addressing COVID monoclonal antibody coverage or domestic biologics manufacturing has been enacted. Reimbursement continues to flow through the Centers for Medicare & Medicaid Services (CMS) administrative mechanisms, not statute, and federal procurement decisions remain a key revenue driver for the company.

The Bottom Line

What Forbes Tate Brings

With King & Spalding out, Forbes Tate Partners remains Invivyd's only outside lobbying firm. The firm registered to represent Invivyd in August 2025 and reported $60,000 in first quarter 2026 fees, the most of any outside firm working for the company.

Forbes Tate Partners is working on infectious disease and health issues for Invivyd. The firm's registered lobbyists on the account are Barrett Thornhill and Zach Williams.

King & Spalding's two lobbyists on the Invivyd account, David Stone and Steve Kupka, are active across the firm's broader client base. Stone has appeared on healthcare and energy client filings, while Kupka is among the firm's most frequently listed lobbyists, appearing across healthcare, energy, manufacturing, and government services engagements.

The Takeaway

Invivyd ended a lobbying engagement that never really got started. No fees changed hands, no legislation was named in the disclosures, and the relationship lasted less than a month. The company's government affairs work continues through Forbes Tate and its in-house lobbyist, focused on the same health and manufacturing issues that King & Spalding was brought in to address. With Phase 3 data for VYD2311 expected in the coming months and federal reimbursement policy still unsettled, Invivyd's need for effective congressional engagement continues.

Access the Legis1 platform for comprehensive political news, data, and insights.